# DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

> **NCT07705919** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 50 (estimated)

## Conditions studied

- Borderline Resectable Pancreatic Ductal Adenocarcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- **DRUG:** Fluorouracil
- **DRUG:** Gadolinium-Chelate
- **DRUG:** Gemcitabine
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin Calcium
- **DRUG:** Nab-paclitaxel
- **DRUG:** Oxaliplatin
- **DEVICE:** Point-of-care portable perfusion phantom (P4)

## Key facts

- **NCT ID:** NCT07705919
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07705919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07705919, "DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07705919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*